Yang Lin1,2, Shandong Ye1,3, Yuanyuan He3, Sumei Li3, Yan Chen4, Zhimin Zhai5. 1. School of Medicine, Shandong University, Jinan, Shandong 250100, China. 2. Department of Pediatrics, Anhui Provincial Hospital, Hefei, Anhui 230001, China. 3. Department of Endocrinology, Anhui Provincial Hospital, Hefei, Anhui 230001, China. 4. Endocrinological Laboratory, Anhui Provincial Hospital, Hefei, Anhui 230001, China. 5. Department of Central lab, Anhui Provincial Hospital, Hefei, Anhui 230001, China.
Abstract
OBJECTIVE: To observe the effect of short-term insulin intensive treatment on the monocyte chemoattractant protein-1 (MCP-1) as well as on the nuclear factor-kappa B (NF-κB) expression of peripheral blood monocyte. This is also in addition to observing the serum MCP-1 level in newlydiagnosed type 2 diabetic patients and probing its anti-inflammation effects. SUBJECTS AND METHODS: Twenty newly-diagnosed type 2 diabetic patients were treated with an insulin intensive treatment for 2 weeks. MCP-1 and NF-κB expression on the monocyte surface were measured with flow cytometry, the serum MCP-1 level was measured by enzyme linked immunosorbent assay (ELISA) during pretreatment and post-treatment. RESULTS: After 2 weeks of the treatment, MCP-1 and NF-κB protein expression of peripheral blood monocyte and serum MCP-1 levels decreased significantly compared with those of pre-treatment, which were (0.50 ± 0.18)% vs (0.89 ± 0.26)% (12.22 ± 2.80)% vs (15.53 ± 2.49)% and (44.53 ± 3.97) pg/mL vs (49.53 ± 3.47) pg/mL, respectively (P < 0.01). The MCP-1 expression on monocyte surface had a significant positive relationship with serum MCP-1 levels (r = 0.47, P < 0.01). CONCLUSIONS: Short-term insulin intensive therapy plays a role in alleviating the increased inflammation reaction in type 2 diabetics.
OBJECTIVE: To observe the effect of short-term insulin intensive treatment on the monocyte chemoattractant protein-1 (MCP-1) as well as on the nuclear factor-kappa B (NF-κB) expression of peripheral blood monocyte. This is also in addition to observing the serum MCP-1 level in newlydiagnosed type 2 diabeticpatients and probing its anti-inflammation effects. SUBJECTS AND METHODS: Twenty newly-diagnosed type 2 diabeticpatients were treated with an insulin intensive treatment for 2 weeks. MCP-1 and NF-κB expression on the monocyte surface were measured with flow cytometry, the serum MCP-1 level was measured by enzyme linked immunosorbent assay (ELISA) during pretreatment and post-treatment. RESULTS: After 2 weeks of the treatment, MCP-1 and NF-κB protein expression of peripheral blood monocyte and serum MCP-1 levels decreased significantly compared with those of pre-treatment, which were (0.50 ± 0.18)% vs (0.89 ± 0.26)% (12.22 ± 2.80)% vs (15.53 ± 2.49)% and (44.53 ± 3.97) pg/mL vs (49.53 ± 3.47) pg/mL, respectively (P < 0.01). The MCP-1 expression on monocyte surface had a significant positive relationship with serum MCP-1 levels (r = 0.47, P < 0.01). CONCLUSIONS: Short-term insulin intensive therapy plays a role in alleviating the increased inflammation reaction in type 2 diabetics.
Authors: Jeanie B Tryggestad; Rachana D Shah; Barbara H Braffett; Fida Bacha; Samuel S Gidding; Rose A Gubitosi-Klug; Amy S Shah; Elaine M Urbina; Lorraine E Levitt Katz Journal: Pediatr Diabetes Date: 2020-07-02 Impact factor: 4.866
Authors: Corinna Koebnick; Mary Helen Black; Jun Wu; Yu-Hsiang Shu; Adrienne W MacKay; Richard M Watanabe; Thomas A Buchanan; Anny H Xiang Journal: Br J Nutr Date: 2018-10-30 Impact factor: 3.718